Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer.
Igeneon GmbH, a wholly owned subsidiary of Aphton Corp, is developing IGN-101, an anticancer vaccine containing the EpCAM-targeting aluminum-adsorbed munrine monoclonal antibody 17-1A (edrecolomab), for the potential subcutaneous treatment of epithelial cancers such as colorectal and rectal tumors. By February 2004, Igeneon was seeking to outlicense the drug.
Kirman
Irena
I
Columbia University, 630 W 168 Street, New York City, New York, USA. ik139@columbia.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000276:immunology*; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D000071858:Epithelial Cell Adhesion Molecule; D006801:Humans; D051379:Mice
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015815:Cell Adhesion Molecules; C499379:EPCAM protein, human; D000071858:Epithelial Cell Adhesion Molecule; C400149:Edrecolomab